Padagis, a pharmaceutical manufacturer, announced on Monday that it has received the FDA approval and subsequently launched an AB-rated generic version of Tobradex Ophthalmic Suspension.

The product is used to treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Padagis president and chief executive officer, Sharon Kochan, said, 'This FDA approval and launch demonstrates our commitment to bringing complex, specialised products to patients and customers nationwide who are in search of high quality, affordable specialised healthcare products. The Padagis team partnered with Rafarm to leverage their unique sterile manufacturing skillset in combination with our regulatory and commercial expertise with the overall goal to deliver this important product to the market.'